Targeting intratumoral androgens: statins and beyond
Autor: | Michael T. Schweizer, Evan Y. Yu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Statin medicine.drug_class Reviews Disease Pharmacology urologic and male genital diseases lcsh:RC254-282 Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Medicine Tumor microenvironment business.industry Transporter medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Androgen receptor Abiraterone 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis business |
Zdroj: | Therapeutic Advances in Medical Oncology, Vol 8 (2016) |
ISSN: | 1758-8359 1758-8340 |
Popis: | While initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all men with advanced prostate cancer will eventually progress to the more resistant, and ultimately lethal form of the disease, so called castration-resistant prostate cancer (CRPC). The maintenance of androgens within the prostate cancer microenvironment likely represents one of the key mechanisms by which this transition from hormone-sensitive to CRPC occurs. This can be accomplished either through intratumoral androgen biosynthesis or the active transport of androgens and androgenic precursors into the tumor microenvironment. More recently, preclinical and clinical data supported therapeutic strategies that seek to target these two mechanisms, either through the use of drugs that impair androgen biosynthesis (e.g. inhibiting the steroidogenic enzymes CYP17 and AKR1C3 with abiraterone and indomethacin, respectively) or drugs that inhibit the SLCO transporters responsible for importing androgens (e.g. statins). |
Databáze: | OpenAIRE |
Externí odkaz: |